CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-09 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −8,731 | $43.72 | $382K | 12,086 |
| 2026-02-09 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −8,374 | 0 | ||
| 2026-02-09 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −2,471 | 0 | ||
| 2026-02-04 | Quart Barry D Director | Option exercise 10b5-1 | +2,602 | $15.47 | $40K | 15,148 |
| 2026-02-04 | Quart Barry D Director | Sale 10b5-1 | −2,602 | $45.02 | $117K | 12,546 |
| 2026-02-04 | Quart Barry D Director | Option exercise · Share Option 10b5-1 | −2,602 | 2,800 | ||
| 2026-02-03 | Quart Barry D Director | Option exercise 10b5-1 | +12,528 | $15.47 | $194K | 25,074 |
| 2026-02-03 | Quart Barry D Director | Sale 10b5-1 | −12,528 | $45.27 | $567K | 12,546 |
| 2026-02-03 | Quart Barry D Director | Option exercise · Share Option 10b5-1 | −12,528 | 5,402 | ||
| 2026-02-02 | Quart Barry D Director | Option exercise 10b5-1 | +830 | $15.47 | $13K | 13,376 |
| 2026-02-02 | Quart Barry D Director | Sale 10b5-1 | −830 | $45.00 | $37K | 12,546 |
| 2026-02-02 | Quart Barry D Director | Option exercise · Share Option 10b5-1 | −830 | 17,930 | ||
| 2026-02-01 | Levy Richard S Director | Option exercise | +683 | 19,157 | ||
| 2026-02-01 | Levy Richard S Director | Grant or award · Restricted Share Units | +683 | 683 | ||
| 2026-02-01 | Levy Richard S Director | Option exercise · Restricted Share Units | −683 | 0 | ||
| 2026-01-15 | Tessari Eben CHIEF STRATEGY OFFICER | Grant or award | +365 | $24.16 | $9K | 17,031 |
| 2026-01-15 | Moat Ross CHIEF OPERATING OFFICER | Grant or award | +879 | $24.16 | $21K | 10,294 |
| 2026-01-15 | Megna Michael R CHIEF ACCOUNTING OFFICER | Grant or award | +372 | $24.16 | $9K | 27,418 |
| 2026-01-08 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −12,000 | $41.89 | $503K | 19,086 |
| 2025-12-15 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +6,000 | $8.83 | $53K | 28,714 |
Page 18 of 74 · 1,467 trades